Healthcare

Pacific Edge is dual-listed, trading on both the ASX and New Zealand's NZX, and is headquartered in Dunedin. Its financial statements are reported in New Zealand dollars, an important detail when interpreting results alongside its Australian-dollar share price. This article reviews what is verifiable …

On 13 July 2026, Tetratherix shares gained about 3.04% to close the snapshot at A$6.44, well above the A$2.88 IPO price and within a reported 52-week range extending toward A$7.50. The market capitalisation of about A$184 million places it among the mid-tier of the …

Actinogen is a clinical-stage neuroscience company whose value is closely tied to a single lead asset, Xanamem, and to a pivotal Alzheimer's trial whose results are expected later in 2026. That concentration makes the stock a classic high-risk, high-reward proposition, and modest daily moves …

Dimerix is a clinical-stage biopharmaceutical company whose lead asset, DMX-200, is being tested in a late-stage trial for a serious rare kidney disease and is already the subject of several global licensing agreements. That combination of a fully recruited Phase 3 program and substantial …

The decline came against a backdrop of steady newsflow around Alterity's lead asset, ATH434, an experimental oral therapy for multiple system atrophy (MSA). No single announcement on 13 July 2026 was identified as a clear trigger, but the company has spent the first half …

Investors following Clinuvel Pharmaceuticals Limited (ASX: CUV) have been watching one regulatory question closely: has SCENESSE been approved in Canada? The clear answer, as of the latest update, is no — not yet. The Canadian decision ispending, not granted. Clinuvel filed a Canadian New …

After a year dominated by takeover headlines, Mayne Pharma Group Limited (ASX: MYX) is once again being judged on the thing that ultimately drives a specialty pharmaceutical company: its operating performance. So what does that operating position look like as of the latest update, …